Infliximab-induced autoimmune hepatitis

Alexander Jenkins*, Amy Austin, Kathryn Hughes, Brett Sadowski, Dawn Torres

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Autoimmune hepatitis (AIH) is an inflammatory disorder of the liver with a wide spectrum of disease presentation, from asymptomatic elevations in liver-associated enzymes to acute liver failure. AIH is classically associated with elevated immunoglobulins and autoantibodies, although approximately 20% of patients with features of AIH lack circulating antibodies. Recently, tumour necrosis factor alpha inhibitors have been implicated in several cases of drug-induced AIH which impact treatment regimens for patients with inflammatory bowel disease (IBD). We present a case of infliximab-induced seronegative AIH responding to budesonide therapy with successful alteration of IBD treatment regimen to vedolizumab.

Original languageEnglish
Article numbere239944
JournalBMJ Case Reports
Issue number5
StatePublished - 24 May 2021
Externally publishedYes


  • drugs: Gastrointestinal system
  • hepatitis other
  • ulcerative colitis


Dive into the research topics of 'Infliximab-induced autoimmune hepatitis'. Together they form a unique fingerprint.

Cite this